Latest stories on URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | URGN Stock News
StockTitan58 · neutralgeneral
UroGen, Teva Settle Jelmyto Patent Dispute, License Generic
TipRanks58 · neutralgeneral
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | URGN Stock News
StockTitan50 · neutralproduct/pr
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
Seeking Alpha50 · neutralproduct/pr